Drug intelligence / Profile preview

DWJ1392

Development stage: Phase 1
Lead developer: Daewoong Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

DWJ1392 is a small molecule drug developed by Daewoong Pharmaceutical. It has been investigated in at least one Phase 1 clinical trial to compare its pharmacokinetics and safety profile with DWC20164 in healthy male volunteers. The specific mechanism of action, therapeutic area, and active indications for DWJ1392 have not been disclosed in publicly available sources as of the latest update. There is no evidence that it has reached approval or advanced beyond early-phase clinical trials[1][3].

Beyond the preview

Go deeper on DWJ1392.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWJ1392.

Explore the full profile